Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)
Part of paid clinical trials in New York, New York.
- Sponsor
- NYU Langone Health
- Study ID
- NCT07567027
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Prostate Cancer (Diagnosis)
- Transperineal Cryoablation
Eligibility Criteria
- Sex
- MALE
- Age
- 40 Years - 95 Years
- Healthy Volunteers
- Not accepted
Interventions
- Barrigel Injectable Gel — DEVICEBarrigel is a hyaluronic acid-based absorbable perirectal spacer.
- Cryoablation — PROCEDUREMinimally invasive treatment for both localized and recurrent prostate cancer.
Study Details
The purpose of this study is to evaluate the feasibility, safety, and potential protective benefit of Barrigel, a hyaluronic acid-based rectal spacer, in patients undergoing prostate cryoablation for localized or recurrent prostate cancer. The primary aim is to assess Barrigel thermal stability during cryoablation.
Key Dates
- Start date
- Jun 1, 2026
- Status verified
- Apr 2026
- Primary completion
- Dec 1, 2027
- Completion
- Jun 1, 2028
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: Barrigel PlacementEach subject will undergo transperineal ultrasound-guided Barrigel placement prior to their image-guided prostate cryoablation in the same procedure session.
Primary Outcome Measure
Percentage of cases in which Barrigel remains unfrozen (temperature maintained above 0°C throughout the freeze cycles) [ Time Frame: End of procedure (up to 4 hours) ]
Central Contacts
- Viola Sulollari(646) 825-6300
- Wei Phin Tan, MD646-825-6325
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10016 | - |
Find similar trials in New York, NY
Related Studies
- Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617PHASE1 · Recruiting · Thomas Hope · San Francisco, California
- PSMA PET for Surveillance After Focal TherapyRecruiting · University of Chicago · Chicago, Illinois
- Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate CancerRecruiting · Duke University · Durham, North Carolina
- High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)PHASE2 · Not Yet Recruiting · Cedars-Sinai Medical Center · Los Angeles, California